Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi and Regeneron to expand US access to Praluent

Sanofi and Regeneron to expand US access to Praluent

12th March 2018

Sanofi has announced the launch of a new access to medicines initiative with Regeneron that will help to expand access to their drug Praluent in the US.

The companies will be providing high-risk patients with a reduced net price for Praluent, in alignment with a new value assessment approach developed by the US Institute for Clinical and Economic Review.

Efforts will be focused on patients who are most vulnerable for future cardiovascular events, such as those who have suffered a previous coronary event and are unable to reduce their cholesterol below a healthy level despite maximally-tolerated statin therapy.

The companies will meet with US healthcare providers to to discuss potential net pricing adjustments for those that agree to provide straightforward access for high-risk patients, while working with healthcare professionals to define best practices.

Dr Olivier Brandicourt, chief executive officer of Sanofi, said: "Too many patients in urgent need of additional treatment options on top of statins have faced tremendous hurdles to gain access to this important medicine. We are prepared to improve access and affordability, eliminating burdensome barriers for high-risk patients in need."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.